Detection, evaluation, and management of iron-restricted erythropoiesis

被引：296

作者：

Goodnough, Lawrence Tim ^{[1
,2
]}

Nemeth, Elizabeta ^{[3
,4
]}

Ganz, Tomas ^{[3
,4
]}

机构：

[1] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA

来源：

BLOOD | 2010年 / 116卷 / 23期

关键词：

RECOMBINANT-HUMAN-ERYTHROPOIETIN; RETICULOCYTE HEMOGLOBIN CONTENT; SERUM TRANSFERRIN RECEPTOR; INTRAVENOUS IRON; DEFICIENCY ANEMIA; CHRONIC DISEASE; RED-CELL; STIMULATING AGENTS; FERRIC GLUCONATE; CONTROLLED-TRIAL;

D O I：

10.1182/blood-2010-05-286260

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Progress in our understanding of iron-restricted erythropoiesis has been made possible by important advances in defining the molecular mechanisms of iron homeostasis. The detection and diagnostic classification of iron-restricted erythropoiesis can be a challenging process for the clinician. Newer assays for markers of inflammation may allow more targeted management of the anemia in these conditions. The availability of new intravenous iron preparations provides new options for the treatment of iron-restricted erythropoiesis. This review summarizes recent advances regarding the detection, evaluation, and management of iron-restricted erythropoiesis. (Blood. 2010;116(23):4754-4761)

引用

页码：4754 / 4761

页数：8

共 77 条

[1] Hyporesponsiveness to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: The Many Faces of Inflammation
Adamson, John W.
[J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2009, 16 (02) : 76 - 82
[2] ALI MAM, 1978, CAN MED ASSOC J, V118, P945
[3] Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms
Annibale, B
Capurso, G
Chistolini, A
D'Ambra, G
DiGiulio, E
Monarca, B
DelleFave, G
[J]. AMERICAN JOURNAL OF MEDICINE, 2001, 111 (06) : 439 - 445
[4] [Anonymous], AM J KIDNEY DIS S3
[5] Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
Ashby, Damien R.
Gale, Daniel P.
Busbridge, Mark
Murphy, Kevin G.
Duncan, Neill D.
Cairns, Tom D.
Taube, David H.
Bloom, Stephen R.
Tam, Frederick W. K.
Chapman, Richard
Maxwell, Patrick H.
Choi, Peter
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 505 - 508
[6] Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial
Auerbach, M
Ballard, H
Trout, JR
McIlwain, M
Ackerman, A
Bahrain, H
Balan, S
Barker, L
Rana, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1301 - 1307
[7] Ferumoxytol as a New, Safer, Easier-to-Ad minister Intravenous Iron: Yes or No?
Auerbach, Michael
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (05) : 826 - 829
[8] The role of intravenous iron in anemia management and transfusion avoidance
Auerbach, Michael
Goodnough, Lawrence Tim
Picard, Dan
Maniatis, Alice
[J]. TRANSFUSION, 2008, 48 (05) : 988 - 1000
[9] Auerbach M, 2008, ANN ONCOL, V19, P3
[10] Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
Bastit, Laurent
Vandebroek, An
Altintas, Sevilay
Gaede, Bernd
Pinter, Tamas
Suto, Tamas S.
Mossman, Tony W.
Smith, Kay E.
Vansteenkiste, Johan F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1611 - 1618

← 1 2 3 4 5 6 7 8 →